West Michigan Cancer Center & Institute for Blood Disorders (WMCC), a collaboration of Ascension Borgess and Bronson Healthcare Group, has named Bridget VandenBussche to lead the organization as Interim Executive Director. VandenBussche takes the helm of WMCC after two and a half years as director of quality improvement and risk. She has been with the cancer center since 2011.
VandenBussche has 15 years’ experience in quality improvement and public health management, including five years at Borgess Medical Center in Kalamazoo. She completed a Bachelor of Arts degree in accounting from Michigan State University in East Lansing and is a certified professional in healthcare risk management. She also earned BLS certification for healthcare providers, is black belt certified in Six Sigma and is a Crisis Prevention Institute instructor.
“I am excited, humbled and honored to lead WMCC as medical oncology and infusion services make their long-planned transition to our partner hospitals,” said VandenBussche. “I look forward to working collaboratively with Borgess and Bronson to help shape the future of all the treatment services we provide at our main campus for patients with cancer and blood disorders. The demand for radiation therapy, surgery and gynecologic oncology services continues to grow and I embrace the opportunity to work on our center’s long-term strategy to serve this community’s needs,” she added.
“Bridget has a deep knowledge of WMCC, based on her experience in quality and risk,” said John Hayden, WMCC Board Chairman. “She is a perfect fit to lead the organization into the next decade as treatment options for cancer and blood disorders evolve with our changing healthcare landscape.”